GlassScriptPhysician profile
Amitabh Goel
NPI 1669408910
$5,763.61
in general payments reported to CMS, 2019-2025
33 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $1,392 · 2021: $829 · 2022: $1,365 · 2023: $638 · 2024: $476 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $1,504.90 | 2020-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $958.18 | 2021-2024 | Proclaim, Axium |
| Boston Scientific Corporation | $594.92 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept |
| Relievant Medsystems, INC. | $557.80 | 2021-2023 | Intracept |
| Medtronic, INC. | $311.12 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Saluda Medical Americas, INC. | $276.58 | 2024-2025 | Evoke |
| Collegium Pharmaceutical, INC. | $250.57 | 2019-2024 | Xtampza |
| Nevro Corp. | $184.84 | 2019-2024 | Senza |
| Curonix LLC | $172.06 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $123.01 | 2021-2023 | |
| Spinal Simplicity, LLC | $108.42 | 2023-2025 | Ha Minuteman G3-R |
| Vertos Medical, INC. | $92.32 | 2022-2024 | Mild Device Kit |
| Stryker Corporation | $81.93 | 2024-2025 | Mild Device Kit |
| Amgen INC. | $81.60 | 2019-2021 | |
| Si-Bone, INC. | $69.83 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $36.61 | 2019 | |
| Spinefrontier, INC. | $32.49 | 2025 | Facetfuse, Sijfuse, Nanofuse |
| Fidia Pharma USA INC. | $31.22 | 2022 | |
| Stimwave Technologies Incorporated | $26.87 | 2019 | |
| Biotronik Nro, INC. | $24.60 | 2025 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.18 | 2025 | Relistor |
| Medline Industries LP | $22.29 | 2022 | |
| Valinor Pharma, LLC | $22.16 | 2025 | Movantik |
| Forte Bio-Pharma LLC | $22.04 | 2024 | Prolate, Nalocet |
| Elutia, INC. | $21.71 | 2023 | |
| Painteq LLC | $21.00 | 2024 | Painteq |
| Globus Medical, INC. | $20.68 | 2025 | Senza |
| Medtronic USA, INC. | $19.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.14 | 2023 | Seglentis |
| Spr Therapeutics, INC | $16.52 | 2022 | |
| Hikma Pharmaceuticals USA | $12.95 | 2022 | |
| Scilex Pharmaceuticals INC. | $12.14 | 2019 | |
| Biodelivery Sciences International, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitabh Goel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.